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Abstract
Background: The high prevalence of hepatitis B virus (HBV) imposes a huge burden of hepatocellular carcinoma
(HCC) in Asia. Surgical resection remains an important therapeutic strategy for HCC. Hepatic inflow occlusion,
known as the Pringle maneuver, is the most commonly used method of reducing blood loss during liver parenchymal
transection. A major issue with this maneuver is ischemia-reperfusion injury to the remnant liver, and the hemodynamic
disturbance it induces in the tumor-bearing liver raises an oncological concern. Given the technical advances in living
donor liver transplantation, vascular occlusion in liver resection can be avoided in experienced hands. The aim of this
study is to compare the perioperative and long-term outcomes of liver resection for HBV-related HCC without versus with
hepatic inflow occlusion.
Methods/design: This study will include eligible patients with HBV-related HCC elected for liver resection. Fifty-seven
patients will be enrolled in each randomization arm to detect a 20 % difference in the serum level of total bilirubin on
postoperative day 5 (80 % power and α= 0.05). The secondary endpoints include procedural parameters, perioperative
liver function and inflammatory response, postoperative morbidity and mortality, and long-term outcomes. Patients will
be followed for up to 5 years. Data will be statistically analyzed on an intention-to-treat basis.
Discussion: This prospective randomized controlled trial is designed to compare the perioperative and long-term
outcomes of liver resection for HBV-related HCC without versus with vascular occlusion. The clinical implications
of these outcomes may change current surgical practice and fill the oncological gaps therein.
Trial registration: Clinicaltrials.gov identifier NCT02563158. Registered on 28 September 2015.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon neoplasm worldwide and the third leading cause of
cancer mortality [1]. In China, HCC is the second most
common cause of cancer-related death [2], and up to
80 % of HCC cases are attributable to hepatitis B virus
(HBV) infection [3, 4].
Surgical resection remains an important therapeutic
strategy for HCC [5]. Intraoperative blood loss and re-
quirement for transfusion have been shown to correlate
well with perioperative morbidity and mortality [6].
Hepatic inflow occlusion, also known as the Pringle
maneuver, is traditionally practiced to reduce blood loss
during liver parenchymal transection [7]. However, this
maneuver induces significant ischemia-reperfusion (IR)
injury to the remnant liver, especially in patients with
underlying liver disease [8]. In China, hepatitis B virus
surface antigen is detected in 70–79 % patients with
cirrhosis of the liver [9, 10]. It is widely accepted that
the cirrhotic liver is particularly sensitive to IR injury
[11, 12]. Furthermore, intermittent application of the
Pringle maneuver, a recommended practice, could in-
duce hemodynamic disturbance to the tumor-bearing
liver, which raises an oncological concern [13, 14].
In living donor liver transplant (LDLT), liver procure-
ment is performed without hepatic vascular occlusion
to reduce the graft warm ischemia time and the IR in-
jury to the donor remnant liver [15, 16]. In recent
years, liver resections, even those done for cirrhotic
livers, have been performed without vascular occlusion
in some centers with expertise [17, 18]. We therefore
hypothesize that liver resection for HBV-related HCC
(the most common etiology in our region) could be
safely performed without vascular occlusion. The
present prospective randomized controlled trial (RCT)
is designed to compare the perioperative and long-term




From January 2016 to November 2017, all patients with
HBV-related HCC scheduled for elective partial hepatec-
tomy in the Department of Hepatobiliary Surgery, Chinese
People’s Liberation Army General Hospital (PLAGH), will
be screened for eligibility for this trial.
Inclusion criteria
Patients who meet the following criteria will be included
in the study:
1. Aged between 18 and 65 years
2. Elective liver resection for HBV-related HCC with
Barcelona-Clínic Liver Cancer stage 0 or A [19]
3. Child-Pugh class A with or without cirrhosis, or
reversed to class A from class B after conventional
therapy
4. Tumors located in either the left or right liver lobe
5. Resection extent is a hemihepatectomy or less
6. Informed consent provided
Exclusion criteria
Patients who meet any of the following criteria will be
excluded from the study:
1. Having comorbidity that contraindicates surgery
2. Undergoing intervention as part of other ongoing
trials with interference with the present study
3. Having undergone nonsurgical interventions that
included portal vein ligation/embolization,
radiofrequency ablation, and transarterial
chemoembolization
4. Scheduled for laparoscopic hepatectomy
5. Requiring concomitant procedures, such as
digestive, vascular, or biliary reconstruction




Randomization will be performed to achieve compar-
ability in terms of known and unknown confounding
variables. The patient allocation will be based on com-
puterized random number generation. All patients eli-
gible for the study will be allocated an opaque envelope
marked only with the patient-specific random number.
The decision regarding the procedure performed will
be sealed inside. The envelope will be opened right be-
fore the preoperative instruction for surgery is given to
the patient, and then the patient will be automatically
assigned to group A (with hepatic inflow occlusion) or
group B (without hepatic inflow occlusion). Owing to
the nature of surgery and the patient’s right of informed
consent, neither the surgeons nor the patients can be
blinded to the procedural details. Only the trial coordi-
nators will be blinded to the information regarding pa-
tient allocation during data processing and analysis.
Withdrawal
Participants can withdraw at any time during the trial at
their own or their legal representative’s request. A par-
ticipant may also be withdrawn if, on the basis of the in-
vestigators’ judgment, continuation of the trial may be
detrimental to the participant’s health. Reasons for all
withdrawals will be recorded in patients’ medical files
and their case report forms (CRFs). All data will be ana-
lyzed according to the intention-to-treat principle [20].
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Ethics, study registration, and consent
The study protocol was approved by the PLAGH
Medical Ethics Committee (S2015-081-01) and is regis-
tered in the ClinicalTrials.gov protocol registration
system (NCT02563158). The study procedure, benefits,
risks, and data management will be introduced in detail
to all eligible participants before they are asked to
provide written informed consent.
Data management and quality assurance
Two independent trial coordinators (YX and AZ), who
will have no contact with any patient, will double-enter
all required data from the CRF and medical records of
patients. The CRF will be completed on the day of
treatment and at the follow-up visits. Reasons for miss-
ing data will be recorded. The principal investigator
and the responsible monitor will routinely check the
completeness and plausibility of the CRF. The partici-
pants will be enrolled strictly according to the inclusion
criteria. The surgeons, statisticians, and trial coordina-
tors will be well-trained to avoid the possible risks of
bias throughout this unmasked trial, such as unfair
evaluation, selection, performance, and attrition. The
attrition of the trial, including patient dropout and/or
withdrawal and missing data, will be prevented and
treated according to published recommendations [21].
The final report will follow the Consolidated Standards
of Reporting Trials (CONSORT) 2010 guidelines as
well as the extension to nonpharmacological interven-
tions [22] (Additional files 1 and 2).
Surgical interventions
Preoperative evaluation
Preoperative management will include imaging studies
and laboratory serum tests (see Endpoints section
below). Other virological and oncological tests to be per-
formed include HBV antigens, antibodies, and DNA;
hepatitis C virus antibody; serum alpha-fetoprotein
(AFP); carcinoembryonic antigen; and carbohydrate anti-
gen 19–9. The Child-Pugh grades for liver function will
be determined on the basis of serum parameters and the
absence or presence of ascites and hepatoencephalopa-
thy [23]. The diagnosis of HCC will be based on the
identification of typical radiological hallmarks of HCC
(hypervascular in the arterial phase with washout in the
portal venous or delayed phase) by four-phase multide-
tector computed tomography (CT) or dynamic contrast-
enhanced magnetic resonance imaging (MRI) [5]. Ac-
cording to the practice recommended by the Ministry of
Health of the People’s Republic of China [24], a more
conservative approach with two imaging techniques or
one technique plus AFP ≥400 ng/ml will be recom-
mended in some suboptimal settings, such as when the
nodule is <2 cm in diameter. Advanced imaging such as
positron emission tomography will be performed in
cases of suspicion of extrahepatic metastases.
Surgical procedures
The same group of surgeons with experience of over
3000 hepatectomies and 200 LDLTs will perform all the
procedures. The abdominal cavity will be opened
through a J-shaped subcostal incision and carefully
searched for peritoneal seeding and extrahepatic metas-
tases. After the liver is mobilized, an intraoperative ultra-
sound will be routinely performed to confirm
preoperative findings and double-check the tumor and
vascular anatomy.
Group A: liver resection with hepatic inflow occlusion
Liver resection will be carried out using the Pringle
maneuver to occlude vascular inflow in cycles of 15 mi-
nutes of clamping plus 5 minutes of unclamping of the
hepatoduodenal ligament. An elastic tourniquet will be
used to encircle and tighten the hepatoduodenal liga-
ment to occlude the hepatic blood inflow. A clamp will
be used to fix the tourniquet. During parenchymal
transection, a hybrid application of electronic cautery,
cavitron ultrasound surgical aspirator, titanium clips,
and silk ligation will be practiced in an institutional
permutation. To reduce bleeding from the hepatic ven-
ous system, <5-mmHg central venous pressure will be
maintained with the patient in a feet-down tilt position
and with volume restriction [25]. After parenchymal
transection, an argon beam coagulator will be used for
hemostasis of the transection surface. Double-drains to
the liver bed will be routinely placed.
Group B: liver resection without hepatic inflow occlusion
The procedural techniques used in group B will be same
as those in group A, but without vascular occlusion. For
the sake of comparability between groups and in cases
of problematic bleeding, the hepatoduodenal ligament
will still be encircled with an elastic tourniquet.
Unplanned conversion from the nonocclusion group to
the occlusion group and its cause will be recorded in the
patient’s CRF and medical record.
Postoperative management
All patients will be transferred to the intensive care unit
(ICU) of the PLAGH Department of Hepatobiliary
Surgery for early postoperative monitoring. Any subse-
quent need for an ICU stay will depend on patient-
specific status. Postoperative serum parameters will be
monitored on a serial basis (see Endpoints section
below).
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Follow-up
Patient follow-up will start upon discharge from the hos-
pital. All patients are required to visit their surgical team
in person 3 and 6 months as well as 1, 2, 3, and 5 years
after surgery or whenever necessary. Routine checkups,
including abdominal ultrasound, CT and/or MRI, and
serum biochemistry and AFP will be performed at each




The primary endpoint will be the serum level of total biliru-
bin (TBil) on postoperative day (POD) 5, which determines
posthepatectomy liver failure (PHLF) in accordance with
the guidelines published by the International Study Group
of Liver Surgery (ISGLS) [26].
Secondary endpoints
The following will be the secondary endpoints:
1. Procedural parameters, including intraoperative
blood loss, requirement for and amount of blood
transfusion, liver transection time, and operative
time
2. Perioperative liver function and inflammatory
response, including serum levels of alanine
aminotransferase (ALT); aspartate aminotransferase
(AST); albumin (ALB); prothrombin time (PT);
international normalized ratio (INR); tumor necrosis
factor-α (TNF-α); interleukin (IL)-1α, IL-2, IL-6,
IL-8, and IL-10; procalcitonin; and C-reactive
protein (CRP) at serial time points (preoperative day
and PODs 1, 3, 5, and 7)
3. Postoperative course, including complications
defined by Clavien-Dindo classification [27], in-
hospital and 90-day mortality, duration of ICU and
hospital stays, and total in-hospital medical
expenditure
4. Long-term outcomes, including 1-, 3-, and 5-year
tumor recurrence rate; overall survival; and disease
(tumor)-free survival (Table 1)
Sample size calculation
Our retrospective data for 17 patients with HBV-related
HCC undergoing liver resection with hepatic inflow oc-
clusion (Pringle maneuver) and 22 patients without in-
flow occlusion showed that the mean ± SD values of
serum TBil on POD 5 were 19.2 ± 6.9 μmol/L in the oc-
clusion group and 15.0 ± 5.3 μmol/L in the nonocclusion
group (J. C., unpublished data). The sample size for the
prospective trial is estimated on the basis of an expect-
ation of a 20 % reduction in serum TBil on POD 5 [26,
28, 29]. On the basis of a two-samples t test with a
statistical difference of 0.05 and a power of 1 − β = 0.90,
a sample size of 57 patients in each randomization arm
will be required. Assuming an estimated withdrawal,
protocol violation, and loss to follow-up rate of 15 %
during the trial, a total number of 134 patients need to
be enrolled. The time frame of patient enrollment will
be approximately 24 months (Fig. 1).
Statistical analysis
The two-sided null hypothesis for the primary endpoint
states that both interventions (liver resection with versus
without hepatic inflow occlusion) lead to similar serum
levels of TBil on POD 5. The alternative hypothesis
states that one intervention performs better with lower
TBil on POD 5 than the other. This null hypothesis will
be tested by an analysis of covariance that adjusts for the
baseline measures (e.g., presence of cirrhosis, preopera-
tive TBil, and remnant liver volume estimated using
CT). We will adjust for the differences in background
characteristics by including them in a multivariable re-
gression model. All background characteristics and sur-
gical outcome measures will be presented as mean ± SD
or median with range for the continuous variables, and
as frequency or percentage for the categorical variables.
A two-sided Student’s t test will be used to compare
continuous parametric variables such as the serum TBil
on POD 5, and a Mann–Whitney U test will be used to
compare discrete or nonparametric variables, as appro-
priate. Categorical variables will be compared using the
chi-square test or Fisher’s exact test. The homogeneity
of patients in the two treatment arms will be described
by comparing the demographic and baseline values. The
serum parameters at serial time points will be analyzed
using repeated-measures analysis of variance. The
Kaplan-Meier method with log-rank test will be used for
survival analysis. The effect of several risk factors on sur-
vival will be analyzed using Cox regression (or propor-
tional hazards regression). A P value <0.05 will be
considered statistically significant. All statistics will be
processed using IBM SPSS version 22.0 software (IBM,
Armonk, NY, USA) A fully specified statistical analysis
plan will be written and approved at least before the
database is unlocked.
Discussion
We hypothesize that liver resection for HBV-related
HCC without vascular occlusion is technically feasible
and perhaps has long-term oncological benefits. To our
knowledge, this is the first prospective RCT to date to
compare the perioperative and long-term outcomes of
liver resection for HBV-related HCC with versus without
hepatic inflow occlusion (Pringle maneuver). Some
points need to be discussed to clarify our study objective
and the study’s clinical implications.
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Table 1 Definition of endpoints
Endpoints Definition
Primary
Postoperative liver function Serum TBil on POD 5 [26]
Secondary
Procedural parameters
Intraoperative blood loss Total blood loss from skin incision to closure, including the amount of blood in the suction containers and the
weight of absorptive materials after subtracting the rinse fluid and ascites
Requirement of blood
transfusion
Indication: massive hemorrhage (>1500 ml) or hemoglobin level <7 g/dl; amount of transfusion
Liver transection time Time from parenchymal dissection to removal of liver specimen (minutes)
Operative time Time from skin incision to closure (in minutes)
Perioperative serum parameters
Liver function Serum ALT, AST, ALB, PT, and INR preoperatively and on PODs 1, 3, 5, and 7
Inflammatory response Serum TNF-α, IL-1α, IL-2, IL-6, IL-8, IL-10, PCT, and CRP preoperatively and on PODs 1, 3, 5, and 7
Postoperative course
Complications Defined by Clavien-Dindo classification (I–IV) [27]
PHLF Increased INR (or need of clotting factors to maintain normal INR) and hyperbilirubinemia on or after POD 5; if
INR or serum bilirubin concentration is increased preoperatively, PHLF is defined by increasing INR and bilirubin
concentration on or after POD 5 (biliary obstruction should be ruled out); graded according to ISGLS [26] as
follows:
A: PHLF requiring no or little change in patient’s clinical management
B: PHLF resulting in deviation from regular clinical management but manageable without invasive treatment
C: PHLF requiring invasive treatment
Bile leakage Increased bilirubin concentration (at least three times greater than the serum level measured at the same time) in
abdominal drain or intraabdominal fluid on or after POD 3, or as need for radiological intervention (e.g.,
interventional drainage) because of biliary collections or relaparotomy resulting from bile peritonitis; graded
according to ISGLS [39] as follows:
A: Bile leakage requiring no or little change in patient’s clinical management
B: Bile leakage requiring change in patient’s clinical management (e.g., additional diagnostic or interventional
procedures) but manageable without relaparotomy, or a grade A bile leakage lasting >1 week
C: Bile leakage requiring relaparotomy
Posthepatectomy
hemorrhage (PHH)
Evidence of intraabdominal bleeding such as frank blood loss via the abdominal drains (e.g., hemoglobin level in
drain fluid >3 g/dl) or detection of intraabdominal hematoma or active hemorrhage by abdominal imaging
(ultrasound, CT, angiography); graded according to ISGLS [40] as follows:
A: PHH requiring transfusion of ≤2 U of PRBCs
B: PHH requiring transfusion of >2 U of PRBCs but manageable without invasive intervention
C: PHH requiring radiological interventional treatment (e.g., embolization) or relaparotomy
Intraperitoneal effusion/
abscess
Any imaging-detected intraperitoneal fluid collection and/or elevation of infectious parameters (CRP >2 mg/dl
and/or leukocytes >100,000/ml), positive physical signs, and bacteriology of abdominal drainage
Pulmonary infection Elevation of infectious parameters (CRP >2 mg/dl and/or leukocytes >100,000/ml) and/or evidence of pulmonary
infiltration on chest x-ray requiring antibiotic therapy
Postoperative ICU/hospital
stay
Time from day of operation through discharge from ICU and/or hospital (days)
Total in-hospital expenditure Costs from admission to discharge (¥/$)
Mortality In-hospital death and 90-day death.
Long-term outcomes
Survival 1-, 3-, and 5-year overall and disease (tumor)-free survival
Tumor recurrence Identification of the typical hallmarks of recurrent HCC foci by dynamic imaging (CT/MRI) plus AFP >400 ng/ml in
suboptimal settings (e.g., foci <2 cm) [24]
Abbreviations: AFP Alpha-fetoprotein, ALB Albumin, ALT Alanine aminotransferase, AST Aspartate aminotransferase, CRP C-reactive protein, CT Computed
tomography, HCC Hepatocellular carcinoma, ICU Intensive care unit, IL Interleukin, INR International normalized ratio, ISGLS International Study Group of Liver
Surgery, MRI Magnetic resonance imaging, PCT Procalcitonin, PHH Posthepatectomy hemorrhage, PHLF Posthepatectomy liver failure, POD Postoperative day,
PRBCs Packed red blood cells, PT Prothrombin time, TBil Total bilirubin, TNF-α Tumor necrosis factor-α
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Trial population
The high prevalence of HBV infection imposes a huge bur-
den of cirrhosis and HCC in Asia. The World Health
Organization reported that the western Pacific and South-
east Asian regions have the highest rates of HBV infection
worldwide. The prevalence in these areas represents >75 %
of the world’s HBV carriers and accounts for >60 % of the
world’s liver cancer cases [30, 31]. It has been projected
that, in the next decade, approximately 80 % of the world’s
HCC cases will be in Asia [32]. RCTs on the Chinese popu-
lation with HBV-related HCC will therefore have a greater
clinical impact. We are in a unique position to enroll the
necessary number of eligible patients.
The study is directed at only the patients with HBV-
related HCC rather than all patients with HCC. The
high prevalence of HBV infection in certain local areas
has been taken into consideration. More importantly,
restricting the underlying disease to HCC will help us to
stratify the patients, reduce confounding variables, and
improve the comparability of the groups. We surmise
that hepatic inflow occlusion may induce a more severe
hepatic IR injury and perioperative inflammatory re-
sponse in patients with HBV-related HCC, owing to the
underlying proinflammatory disease (hepatitis and/or
cirrhosis). The results of the study may provide an
answer to this concern and change the current practice
for treatment of HBV-related HCC.
Trial objective
Various techniques of vascular occlusion have been prac-
ticed to reduce blood loss during liver resection [33].
Hepatic inflow occlusion (the Pringle maneuver) is a long-
standing method used because of its simplicity and proven
efficacy [34]. A major concern with this maneuver is the IR
injury to the remnant liver. As a common consequence of
HBV infection, liver cirrhosis is detected in most cases of
HBV-related HCC [10]. It is generally recognized that the
cirrhotic liver is particularly sensitive to the IR injury [11,
12]. Given the technical advances in LDLT, the Pringle
maneuver could be avoided in liver resection in experi-
enced hands [17, 18]. All these considerations imply that
liver resection without vascular occlusion could be a more
preferred option for patients with HBV-related HCC. The
clinical implications of the outcomes of the present study
may change current clinical practice. Furthermore, the
hemodynamic disturbance to the tumor-bearing liver by
intermittent hepatic inflow occlusion remains an onco-
logical concern [13, 14, 35, 36]. Long-term follow-up of pa-
tients with HCC in this study will provide clinical clues and
perhaps fill current gaps in knowledge.
Fig. 1 Flowchart of the trial
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Trial endpoints
Serum TBil has been used widely as an important par-
ameter for determining PHLF. The ISGLS defines PHLF
as an increased serum TBil on or after POD 5 or an in-
creasing TBil (compared with values at the previous time
point) if TBil is increased preoperatively (INR is an
equivalent parameter in this criterion) [26]. The “50-50”
criterion defines PHLF with PT >50 % (or INR >1.7) and
TBil >50 μmol/L on POD 5 [37]. As a widely agreed
prognostic factor, serum TBil on POD 5 is selected as
the primary endpoint in the present study. In our pilot
study, a 20 % difference in serum TBil on POD 5 was
found between the occlusion and nonocclusion groups.
Although the average TBil levels of both groups were
within acceptable range (15.0 ± 5.3 μmol/L vs. 19.2 ±
6.9 μmol/L), the preliminary data indicated a potential
difference in perioperative outcomes between the two
groups, and its clinical significance might be reflected by
other endpoints. These conclusions are based on analysis
of retrospective data, which could have been influenced
by some confounding variables. The future prospective
RCT will provide more analyzable data.
The secondary endpoints include most perioperative and
long-term parameters. We also added serum inflammatory
factors, such as the IL-1, IL-2, IL-8, IL-10, TNF-α, and
CRP. Hepatic IR injury results in a complex release of in-
flammatory mediators [38]; thus, the perioperative inflam-
matory response would reflect the impact of vascular
occlusion and link it to the subsequent outcomes.
This is to date the first prospective RCT comparing
liver resection for HBV-related HCC with versus without
hepatic inflow occlusion. The results with respect to the
perioperative and long-term outcomes will be analyzed
and discussed upon the completion of data collection.
Trial status
The study protocol was designed in June 2015 and regis-
tered with ClinicalTrials.gov (NCT02563158) in September
2015. Patient enrollment started in January 2016. Twenty
six patients have been enrolled by September 2016.
Additional files
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 123 kb)
Additional file 2: Figure S1. Schedule of enrollment, interventions, and
assessments. (JPG 920 kb)
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